Stryker to host conference call on April 25, 2017
March 27 2017 - 1:01PM
Kalamazoo, Michigan - March 27, 2017 - Stryker
Corporation (NYSE:SYK) announced that it will host a conference
call on Tuesday, April 25, 2017 at 4:30 p.m., Eastern Time, to
discuss the Company's operating results for the quarter ended March
31, 2017 and provide an operational update. Final operating results
for the quarter ended March 31, 2017 will be released at 4:00 p.m.
that day.
To participate in the conference call dial (844)
826-0610 (domestic) or (973) 453-3249 (international) and be
prepared to provide conference ID number 26016220 to the
operator.
A simultaneous webcast of the call will be
accessible via the Company's website at www.stryker.com. The call
will be archived on the Investors page of this site.
A recording of the call will also be available
from 8:00 p.m., Eastern Time, on Tuesday, April 25, 2017, until
11:59 p.m., Eastern Time, on Tuesday, May 2, 2017. To hear this
recording you may dial (855) 859-2056 (domestic) or (404) 537-3406
(international) and enter conference ID number 26016220.
Forward-looking
statements
This presentation may contain information that includes or is based
on forward-looking statements within the meaning of the federal
securities law that are subject to various risks and uncertainties
that could cause our actual results to differ materially from those
expressed or implied in such statements. Such factors include, but
are not limited to: weakening of economic conditions that could
adversely affect the level of demand for our products; pricing
pressures generally, including cost-containment measures that could
adversely affect the price of or demand for our products; changes
in foreign exchange markets; legislative and regulatory actions;
unanticipated issues arising in connection with clinical studies
and otherwise that affect U.S. Food and Drug Administration
approval of new products; changes in reimbursement levels from
third-party payors; a significant increase in product liability
claims; the ultimate total cost with respect to the Rejuvenate and
ABG II matter; the impact of investigative and legal proceedings
and compliance risks; resolution of tax audits; the impact of the
federal legislation to reform the United States healthcare system;
changes in financial markets; changes in the competitive
environment; our ability to integrate acquisitions; and our ability
to realize anticipated cost savings. Additional information
concerning these and other factors is contained in our filings with
the U.S. Securities and Exchange Commission, including our Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q.
Stryker is one of the world's leading medical
technology companies and, together with our customers, we are
driven to make healthcare better. The Company offers a diverse
array of innovative products and services in Orthopaedics,
Medical and Surgical, and Neurotechnology and Spine that help
improve patient and hospital outcomes. Stryker is active in
over 100 countries around the world. Please contact us for
more information at www.stryker.com.
Contacts
For investor inquiries please
contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or
katherine.owen@stryker.com
For media inquiries please
contact:
Yin Becker, Stryker Corporation, 269-385-2600 or
yin.becker@stryker.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Stryker Corporation via Globenewswire
Stryker (NYSE:SYK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stryker (NYSE:SYK)
Historical Stock Chart
From Apr 2023 to Apr 2024